Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F Lehmann

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Pharmacotherapy|January 31, 2018
Validation and Clinical Utility of the hERG IC50:C<sub>max</sub> Ratio to Determine the Risk of Drug-Induced Torsades de Pointes: A Meta-AnalysisDavid F Lehmann, William D Eggleston, Dongliang Wang
Journal of Clinical Pharmacology|November 15, 2003
Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcerDavid F Lehmann, Joseph J Medicis, Patricia D Franklin
Joint Commission Journal on Quality and Patient Safety|May 14, 2009
Using order entry for alerts of dose conversion between potassium salts to prevent physician dosing errorsDavid F Lehmann, Paul Lipinoga, John DeGrazio, et al.
Clinical Pharmacology and Therapeutics|March 4, 2006
Profound metoprolol-induced bradycardia precipitated by acetaminophen-propoxypheneJeanna M Marraffa, Li Lang, Gilbert Ong, et al.
Journal of Clinical Pharmacology|January 9, 2025
Street Pharmacology: Toxico-Dermatology of Injection Drug UseDavid F Lehmann, Aryana Nazem, Jeanna Marraffa, et al.
British Journal of Clinical Pharmacology|August 31, 2006
The combination of nuclear and mitochondrial mutations as a risk factor for idiosyncratic toxicityDaria LaRocca, David F Lehmann, Andras Perl, et al.
Pharmacotherapy|September 20, 2016
Clinical Application and Pharmacodynamic Monitoring of Apixaban in a Patient with End-Stage Renal Disease Requiring Chronic HemodialysisWesley D Kufel, Adam S Zayac, David F Lehmann, et al.
Journal of Clinical Pharmacology|June 2, 2026
Street Pharmacology: The Mechanistic Basis of Clinical Pharmacology Underlying the Microdosing Method of Buprenorphine-Naloxone With a Focus on the Unhoused PopulationDavid F Lehmann, Olivia Tanner, Eliesha Pepple, et al.
International Journal of Nephrology|March 12, 2013
To bind or to let loose: effectiveness of sodium polystyrene sulfonate in decreasing serum potassiumShaifali Sandal, Hatim Karachiwala, John Noviasky, et al.
Journal of Clinical Pharmacology|September 26, 2023
Do P-glycoprotein Medications Alter the Risk of Ventriculoperitoneal Shunt in Adults with Hydrocephalus?Jason R Grullon, George W Koutsouras, Nneka F Onwumere, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Pharmacotherapy|January 31, 2018
Validation and Clinical Utility of the hERG IC50:C<sub>max</sub> Ratio to Determine the Risk of Drug-Induced Torsades de Pointes: A Meta-AnalysisDavid F Lehmann, William D Eggleston, Dongliang Wang
Journal of Clinical Pharmacology|November 15, 2003
Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcerDavid F Lehmann, Joseph J Medicis, Patricia D Franklin
Joint Commission Journal on Quality and Patient Safety|May 14, 2009
Using order entry for alerts of dose conversion between potassium salts to prevent physician dosing errorsDavid F Lehmann, Paul Lipinoga, John DeGrazio, et al.
Clinical Pharmacology and Therapeutics|March 4, 2006
Profound metoprolol-induced bradycardia precipitated by acetaminophen-propoxypheneJeanna M Marraffa, Li Lang, Gilbert Ong, et al.
Journal of Clinical Pharmacology|January 9, 2025
Street Pharmacology: Toxico-Dermatology of Injection Drug UseDavid F Lehmann, Aryana Nazem, Jeanna Marraffa, et al.
British Journal of Clinical Pharmacology|August 31, 2006
The combination of nuclear and mitochondrial mutations as a risk factor for idiosyncratic toxicityDaria LaRocca, David F Lehmann, Andras Perl, et al.
Pharmacotherapy|September 20, 2016
Clinical Application and Pharmacodynamic Monitoring of Apixaban in a Patient with End-Stage Renal Disease Requiring Chronic HemodialysisWesley D Kufel, Adam S Zayac, David F Lehmann, et al.
Journal of Clinical Pharmacology|June 2, 2026
Street Pharmacology: The Mechanistic Basis of Clinical Pharmacology Underlying the Microdosing Method of Buprenorphine-Naloxone With a Focus on the Unhoused PopulationDavid F Lehmann, Olivia Tanner, Eliesha Pepple, et al.
International Journal of Nephrology|March 12, 2013
To bind or to let loose: effectiveness of sodium polystyrene sulfonate in decreasing serum potassiumShaifali Sandal, Hatim Karachiwala, John Noviasky, et al.
Journal of Clinical Pharmacology|September 26, 2023
Do P-glycoprotein Medications Alter the Risk of Ventriculoperitoneal Shunt in Adults with Hydrocephalus?Jason R Grullon, George W Koutsouras, Nneka F Onwumere, et al.
Pageof 3